Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 0: clinchem.2006.069054v1, 2006; 10.1373/clinchem.2006.069054
This Article
Right arrow Full Text (PDF)
Right arrow 069054.Supplemental data
Right arrow All Versions of this Article:
clinchem.2006.069054v1
52/9/1728    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pirnay, S. O.
Right arrow Articles by Huestis, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pirnay, S. O.
Right arrow Articles by Huestis, M. A.

Received on February 19, 2006
Accepted on June 8, 2006

Drug Monitoring and Toxicology

Sensitive Gas Chromatography-Mass Spectrometry Method for Simultaneous Measurement of MDEA, MDMA, and Metabolites HMA, MDA, and HMMA in Human Urine

Stephane O. Pirnay 1, Tsadik T. Abraham 1, Marilyn A. Huestis 1*

1 Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, MD

* To whom correspondence should be addressed. E-mail: mhuestis{at}intra.nida.nih.gov.

Background: A sensitive gas chromatography-mass spectrometry method was developed and validated for the simultaneous measurement of MDEA, MDMA, and its metabolites, HMA, MDA, and HMMA, in human urine.

Methods: We hydrolyzed 1 mL urine, fortified with MDMA-d5, MDA-d5, and MDEA-d6, with 100 µL of concentrated hydrochloric acid at 120 °C for 40 min. One hundred microliters 10 N sodium hydroxide and 3 mL phosphate buffer 0.1 N (pH 6.0) were added to hydrolyzed urine specimens before solid-phase extraction. After elution and evaporation, we derivatized extracts with heptafluorobutyric acid anhydride and analyzed with gas chromatography-mass spectrometry operated in EI-selected ion-monitoring mode.

Results: Limits of quantification were 25 µg/L for MDEA, MDMA, and its metabolites. Calibration curves were linear to 5000 µg/L for MDEA, MDMA, HMA, MDA, and HMMA, with a minimum r2 > 0.99. At 3 concentrations spanning the linear dynamic range of the assay, mean overall extraction efficiencies from urine were >85.5% for all compounds of interest. Intra- and inter-assay precision, produced as CV, were <15% for all drugs at 30, 300, and 3000 µg/L.

Conclusions: This gas chromatography-mass spectrometry assay provides adequate sensitivity and performance characteristics for the simultaneous quantification of MDEA, MDMA, and its metabolites HMMA, MDA, and HMA in human urine. The method meets and exceeds the requirements of the proposed Substance Abuse and Mental Health Administration's guidelines for federal workplace drug testing of MDEA and MDMA in urine.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by the American Association for Clinical Chemistry.